Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, Aledex, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Comment by ksmits16on Dec 29, 2011 10:24am
173 Views
Post# 19356557

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE

Thanks. But I still think the buying is material. Do you have a spare $20K that you want to buy into the company? The board member did. Considering that he's probably a board member of other companies and has other investments, using his investment money to dump into KNE is a positive sign, no matter what everyone's personal opinion is on materiality. Especially since he is involved in the capital markets. Probably is getting all his institutional buddies in on it too at these low levels. 

 

It outlines that the DispersinB is still in application for stuff beyong household use. Still what do you want from a $5M market cap company? If DispersinB was the cure for cancer it would be a $200M market cap now. It's already been approved for household use and the US Army likes it. There's a good chance it'll be approved for more.

 

Also, I'm willing to bet that the Lysol product line is worth more to Reckitt (the maker of Lysol) than $5M. So even if its only good for household, it's worth a lot more than 9 cents anyways.

 

True on the warrants but that's still not that much, it's at much higher prices than 9 cents, and if exercised, the company gets money in the bank. Warrants are anti-dilutive tools when at higher strike prices. If KNE is $1, then yea, watch out for those warrants. 

 

Bullboard Posts